Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Atara Biotherapeutics (ATRA) Revenue (2022 - 2026)

Atara Biotherapeutics filings provide 5 years of Revenue readings, the most recent being $516000.0 for Q1 2026.

  • On a quarterly basis, Revenue fell 99.47% to $516000.0 in Q1 2026 year-over-year; TTM through Mar 2026 was $23.1 million, a 88.41% decrease, with the full-year FY2025 number at $120.8 million, down 6.33% from a year prior.
  • Revenue hit $516000.0 in Q1 2026 for Atara Biotherapeutics, down from $1.6 million in the prior quarter.
  • In the past five years, Revenue ranged from a high of $98.1 million in Q1 2025 to a low of $221000.0 in Q4 2022.
  • Median Revenue over the past 5 years was $6.1 million (2022), compared with a mean of $19.9 million.
  • Biggest five-year swings in Revenue: skyrocketed 3511.6% in 2024 and later crashed 99.47% in 2026.
  • Atara Biotherapeutics' Revenue stood at $221000.0 in 2022, then skyrocketed by 2106.33% to $4.9 million in 2023, then skyrocketed by 571.72% to $32.8 million in 2024, then crashed by 95.13% to $1.6 million in 2025, then crashed by 67.65% to $516000.0 in 2026.
  • The last three reported values for Revenue were $516000.0 (Q1 2026), $1.6 million (Q4 2025), and $3.5 million (Q3 2025) per Business Quant data.